Intensity bolsters survival data for its intratumoral cancer therapy The company’s stock shot up by approximately 394%, driven by the cancer therapy's strong overall survival and disease control results.

Intensity Therapeutics's INT230-6, a tumor-injectable therapy, improved survival and showed abscopal effects in patients with advanced, refractory cancers.

#News #Cancer #Oncology #CancerResearch #IJTHS #CancerSurvival #ClinicalTrial

Intensity bolsters survival data for its intratumoral cancer therapy The company’s stock shot up by approximately 394%, driven by the cancer therapy's strong overall survival and disease control results.

Intensity Therapeutics's INT230-6, a tumor-injectable therapy, improved survival and showed abscopal effects in patients with advanced, refractory cancers.

#News #Cancer #Oncology #CancerResearch #IJTHS #CancerSurvival #ClinicalTrial